Straumann STMN.SW
Straumann is a Swiss global leader in dental implants, orthodontics, and digital solutions for dentistry, selling its products to dentists and laboratories through a global network of direct distribution and partners. Straumann shows excellent financial health (ND/EBITDA of 0.08) and a solid competitive moat (ROIC of 24%), but its valuation is demanding (P/E of 42.75) and growth is moderate (revenue +2.3%), limiting the appeal at these prices.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Straumann is a Swiss global leader in dental implants, orthodontics, and digital solutions for dentistry, selling its products to dentists and laboratories through a global network of direct distribution and partners. Straumann shows excellent financial health (ND/EBITDA of 0.08) and a solid competitive moat (ROIC of 24%), but its valuation is demanding (P/E of 42.75) and growth is moderate (revenue +2.3%), limiting the appeal at these prices.
Score by category
| Category | Score |
|---|---|
| Financial health | 8.3 |
| Quality / Moat | 7.8 |
| Valuation | 3.9 |
| Growth | 5.2 |
| Dividend | 5.7 |
| Momentum | 5.3 |
| Risk & Context | 3.9 |
OVERALL SCORE: 5.9/10
Context and risks
Moderate governance/regulatory risk in Switzerland. There is no material exposure to current macro factors (rates, oil, geopolitics) that directly affects its dental implantology business.
News considered in the analysis
- HSIC or SAUHY: Which Is the Better Value Stock Right Now? — Listículo comparativo de valoración sin información nueva sobre Straumann.
- HSIC vs. SAUHY: Which Stock Is the Better Value Option? — Listículo comparativo de valoración sin información nueva sobre Straumann.
- Health Care Roundup: Market Talk — Resumen de mercado genérico sin información específica sobre Straumann.
- ALGN vs. SAUHY: Which Stock Is the Better Value Option? — Listículo comparativo de valoración sin información nueva sobre Straumann.
- ALGN or SAUHY: Which Is the Better Value Stock Right Now? — Listículo comparativo de valoración sin información nueva sobre Straumann.
Verdict: Hold; the quality of the business is high, but the current valuation offers no margin of safety.
Main risk: The main risk is the demanding valuation (P/E of 42.75) in an environment of slow revenue growth (2.3%), leaving little room for error if growth does not accelerate or if the market adjusts multiples.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →